ClinVar Miner

Submissions for variant NM_000090.3(COL3A1):c.1856C>T (p.Pro619Leu) (rs373838193)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000621849 SCV000738552 uncertain significance Cardiovascular phenotype 2017-05-10 criteria provided, single submitter clinical testing Lines of evidence used in support of classification: Insufficient evidence
CSER_CC_NCGL; University of Washington Medical Center RCV000319906 SCV000503543 uncertain significance Ehlers-Danlos syndrome, type 4 2016-08-01 no assertion criteria provided research Found in patient having exome sequencing for an unrelated indication. No known history of Ehlers-Danlos syndrome, type IV
GeneDx RCV000523302 SCV000617055 uncertain significance not provided 2017-11-08 criteria provided, single submitter clinical testing A variant of uncertain significance has been identified in the COL3A1 gene. The P619L variant has not been published as a pathogenic variant, nor has it been reported as a benign variant to our knowledge. This variant has been identified in one other unrelated individual referred for Marfan/TAAD genetic testing at GeneDx; however, segregation data for this individual is absent. P619L was not observed with any significant frequency in approximately 6,500 individuals of European and African American ancestry in an external variant database, indicating it is not a common benign variant in these populations. The P619L variant is a semi-conservative amino acid substitution, which may impact secondary protein structure as these residues differ in some properties. This substitution occurs at a position that is conserved across species. However, although the P619L variant occurs within a in the triple helical region of the COL3A1 gene, it does not affect a Glycine residue in a Gly-X-Y motif, where the majority of pathogenic missense variants occur (Stenson et al., 2014; Symoens et al., 2012). Furthermore, in silico analysis is inconsistent in its predictions as to whether or not P619L is damaging to the protein structure/function.Therefore, based on the currently available information, it is unclear whether this variant is pathogenic or benign.
Illumina Clinical Services Laboratory,Illumina RCV000319906 SCV000425520 uncertain significance Ehlers-Danlos syndrome, type 4 2016-06-14 criteria provided, single submitter clinical testing
Invitae RCV000319906 SCV000631634 uncertain significance Ehlers-Danlos syndrome, type 4 2018-11-27 criteria provided, single submitter clinical testing This sequence change replaces proline with leucine at codon 619 of the COL3A1 protein (p.Pro619Leu). The proline residue is highly conserved and there is a moderate physicochemical difference between proline and leucine. This variant is present in population databases (rs373838193, ExAC 0.01%). This variant has not been reported in the literature in individuals with a COL3A1-related disease. ClinVar contains an entry for this variant (Variation ID: 333057). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. In summary, this variant has uncertain impact on COL3A1 function. The available evidence is currently insufficient to determine its role in disease. Therefore, it has been classified as a Variant of Uncertain Significance.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.